Research Article

Gene Ontology and KEGG Enrichment Analyses of Genes Related to Age-Related Macular Degeneration

Jian Zhang,^{1,2} ZhiHao Xing,³ Mingming Ma,^{1,2} Ning Wang,^{1,2} Yu-Dong Cai,⁴ Lei Chen,⁵ and Xun Xu^{1,2}

¹ Department of Ophthalmology, Shanghai First People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China

² Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai First People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China

³ The Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Jiaotong University School of Medicine and Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200025, China

⁴ Institute of Systems Biology, Shanghai University, Shanghai 200444, China

⁵ College of Information Engineering, Shanghai Maritime University, Shanghai 201306, China

Correspondence should be addressed to Lei Chen; chen_leil@163.com and Xun Xu; drxuxun@tom.com

Received 13 June 2014; Accepted 21 July 2014; Published 6 August 2014

Academic Editor: Tao Huang

Copyright © 2014 Jian Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Identifying disease genes is one of the most important topics in biomedicine and may facilitate studies on the mechanisms underlying disease. Age-related macular degeneration (AMD) is a serious eye disease; it typically affects older adults and results in a loss of vision due to retina damage. In this study, we attempt to develop an effective method for distinguishing AMD-related genes. Gene ontology and KEGG enrichment analyses of known AMD-related genes were performed, and a classification system was established. In detail, each gene was encoded into a vector by extracting enrichment scores of the gene set, including it and its direct neighbors in STRING, and gene ontology terms or KEGG pathways. Then certain feature-selection methods, including minimum redundancy maximum relevance and incremental feature selection, were adopted to extract key features for the classification system. As a result, 720 GO terms and 11 KEGG pathways were deemed the most important factors for predicting AMD-related genes.

1. Introduction

Age-related macular degeneration (AMD or ARMD) is a chronic, progressive eye disorder that primarily occurs in elders (>50 years) and has become a major cause of blindness and visual impairment in developed countries as well as the third major cause globally [1, 2]. In an Asian population aged 40–79 years, the morbidities of early and late AMD were 6.8% and 0.56%, respectively [3]. Further, AMD is likely to increase with a longer life expectancy. Due to retina damage, AMD typically results in vision loss, which can render daily activities difficult, such as reading, watching TV, and recognizing faces [4]. There are two typical types of AMD: dry AMD and wet AMD. Dry AMD is the major

type of AMD and accounts for approximately 80% of cases; no efficient surgical or medical treatments are available. It typically causes mild vision loss, which develops slowly. However, it can cause vision loss through retinal pigment epithelial layer atrophy, which results in photoreceptor loss (rods and cones) in the central portion of the eye. Wet AMD is caused by choroidal neovascularization (CNV), wherein new blood vessels grow in choriocapillaries through the Bruch's membrane. Leaking and bleeding of these vessels can damage the rods and cones, which lead to rapidly deteriorating vision. Thus, wet AMD accounts for 90% of AMD cases with severe visual impairment.

The AMD etiology is complex. AMD results from both genetic and environmental factors; however, the underlying

mechanisms are unclear. Moreover, previous studies have demonstrated strong correlations between AMD and multiple environmental factors. In addition to age, many risk factors are correlated with AMD, such as cigarette smoking [5], oxidative stress [6–8], hypertension, previous cataract surgery, higher body mass index, a history of cardiovascular disease, and higher plasma fibrinogen [9].

AMD is characterized by complex traits. Moreover, mutant protein expression may begin early in AMD patients, and symptoms associated with AMD do not manifest until a long time thereafter. Often only clinical information for a single generation is available for studies; thus, it is difficult to detect AMD phenotypic heterogeneity and determine the underlying mechanisms. Initially, through early linkage studies on small families, several genetic loci at chromosomes 9p24, 10q26, and 15q21 [10] and 1q31, 10q26, and 17q25 [11] were identified and verified. A GWAS study greatly increased our understanding of AMD risk loci. Subsequently, more AMD-related genes have been identified, such as *C2* [12], *CFH* [13], *CFI* [14], *LIPC* [15], *CETP*, *TIMP3* [16], and *TNFRSF10A* [17]. Recently a large-scale GWAS analysis of more than 17,000 AMD cases indicated 19 other AMD loci, in which 7 loci were novel and near the genes *IER3-DDR1*, *COL8A1-FILIPIL*, *SLC16A8*, *TGFBRI*, *ADAMTS9*, *RAD51B*, and *B3GALT1* [18]. Several studies have evaluated the impact of susceptibility genes on AMD onset and progression. For instance, *CFH* gene mutations yield a high risk of AMD. Compared with the normal homozygous genotype, individuals with heterozygous and homozygous *CFH* exhibited a 4.6-fold or 7.4-fold increased AMD risk, respectively [19].

AMD is a disease with complex inheritance patterns, and it may be difficult to discover individual susceptibility genes due to multiple genetic and environmental effects and interactions. Identifying several genetic loci revealed that several important biological pathways are involved in AMD pathogenesis, such as the cholesterol, lipid metabolism pathway, complement pathway, extracellular matrix pathway, oxidative stress pathway, and angiogenesis signaling pathway in [20–22], which provides a foundation for systematically analyzing the biological processes underlying AMD. Gene ontology (GO) is a major bioinformatics tool that standardizes representation and the product attributes of genes across species [23]. The Kyoto Encyclopedia of Genes and Genomes (KEGG) [24, 25] pathway database is a collection of manually drawn diagrams and comprehensive inferences for pathway mapping. Based on the gene ontology and KEGG pathway materials, we analyzed the GO and KEGG enrichments for known AMD-related genes, which were retrieved from the Retina International website (<http://www.retina-international.org/files/sci-news/remacdy.htm>) or the published literature. To extract the distinctive features of these genes, certain genes, which were not reported as AMD-related genes, were randomly selected from Ensemble. Each investigated gene was encoded into numeric vectors consisting of enrichment scores of the gene set, including it and its direct neighbors in STRING, and the GO terms or KEGG pathways. Based on certain feature-selection methods and SMO as the prediction engine, certain important GO terms and KEGG pathways were discovered that were

deemed important for identifying AMD-related genes. Analyses suggest that certain such genes relate directly or indirectly to AMD formation or development.

2. Materials and Methods

2.1. Dataset. The known AMD-related genes were retrieved from the Retina International website (<http://www.retina-international.org/files/sci-news/remacdy.htm>, recent update from March 24, 2010) and the literature. Specifically, 16 genes are from Retina International; three genes for the complement system proteins factor H (*CFH*), factor 3 (*C3*), and factor B (*CFB*), which are strongly related with a person's risk for developing AMD, are employed; *HTRA1* is from [26, 27]; *ABCR* is from [28]; 2 genes are from [29, 30]; and 23 genes are from [18]. Finally, 39 known AMD-related genes were collected; these genes are referred to as “positive genes” and compose the gene set S_p . To analyze the differences between the positive genes and other genes, we randomly selected 1,950 genes (50 times the number of positive genes) from Ensemble that were not in S_p ; these 1,950 genes are referred to as “negative genes” and compose the set S_n . The Ensemble IDs for the positive and negative genes are in Supplementary Material I available online at <http://dx.doi.org/10.1155/2014/450386>.

The negative genes outnumbered the positive genes; thus, we confronted an imbalanced dataset. Encouraged by certain studies that have managed this type of data [31, 32], the following strategy was adopted. The negative genes were equally and randomly split into 10 portions $S_n^1, S_n^2, \dots, S_n^{10}$ (i.e., $S_n = S_n^1 \cup S_n^2 \cup \dots \cup S_n^{10}$ and $S_n^i \cap S_n^j = \emptyset$ for $i \neq j$). For each S_n^i , we combined the genes in S_p and S_n^i to comprise the i th datasets D_i (i.e., $D_i = S_p \cup S_n^i$).

2.2. Feature Construction. To analyze the differences between the positive and negative genes, each gene must be represented by certain features that can then be processed by certain computer programs. Here, we adopted gene ontology (GO) and KEGG enrichment to compute numerical values that represent each gene.

GO enrichment indicates the relationship between genes and GO terms. For each gene g and each GO term GO_j , a score is generated, which is typically referred to as the gene ontology enrichment score and defined as the $-\log_{10}$ of the hypergeometric test P value [33–35] for a gene set G consisting of g 's direct neighbors in STRING and the GO term GO_j that can be computed as follows:

$$ES_{GO}(g, GO_j) = -\log_{10} \left(\sum_{k=m}^n \frac{\binom{M}{m} \binom{N-M}{n-m}}{\binom{N}{n}} \right), \quad (1)$$

where N denotes the overall number of proteins in humans, M denotes the number of proteins annotated in the gene ontology term GO_j , n denotes the number of proteins in G , and m denotes the number of proteins in G that are annotated in the gene ontology term GO_j . If the score is large for one gene and one GO term, the gene and GO term likely

have a strong relationship; there were 12,877 gene ontology enrichment scores.

Similarly, for each gene g and each KEGG pathway P_j , the KEGG enrichment score is defined as the $-\log_{10}$ of the hypergeometric test P value [35, 36] for a gene set G that consists of g 's direct neighbors in STRING and the KEGG pathway P_j , which can be calculated as follows:

$$ES_{KEGG}(g, P_j) = -\log_{10} \left(\sum_{k=m}^n \frac{\binom{M}{m} \binom{N-M}{n-m}}{\binom{N}{n}} \right), \quad (2)$$

where N denotes the overall number of proteins in humans, M denotes the number of proteins annotated in the KEGG pathway P_j , n denotes the number of proteins in G , and m denotes the number of proteins in G that are annotated in the KEGG pathway P_j . Additionally, a higher KEGG enrichment score between g and P_j indicates a stronger relationship; 239 features were KEGG enrichment scores.

Accordingly, each gene g can be represented by 12,877 gene ontology enrichment scores and 239 KEGG enrichment scores, which can be formulated as follows:

$$v(g) = (ES_{GO}(g, GO_1), \dots, ES_{GO}(g, GO_{12877}), ES_{KEGG}(g, P_1), \dots, ES_{KEGG}(g, P_{239}))^T. \quad (3)$$

2.3. Prediction Method and Accuracy Measurement. Weka [37] is a collection of many state-of-the-art machine-learning algorithms and has been used to solve various biological problems [38–42]. One classifier, which is referred to as SMO, was adopted herein as the classification method; it implements John Platt's sequential minimal optimization algorithm to solve the optimization problem that should be settled during training of a support vector classifier. The kernel function can be polynomial or Gaussian [43, 44].

The predicted results for a two-class classification problem can be represented by a confusion matrix consisting of four entries: a true positive (TP), a true negative (TN), false positives (FP), and a false negative (FN) [45, 46]. Accordingly, the prediction accuracy (ACC), specificity (SP), and sensitivity (SN) can be computed as follows:

$$\begin{aligned} ACC &= \frac{TP + TN}{TP + TN + FP + FN}, \\ SP &= \frac{TN}{TN + FP}, \\ SN &= \frac{TP}{TP + FN}. \end{aligned} \quad (4)$$

However, in each dataset D_i , the number of negative genes was 5 times as many as the number of positive genes, which is still imbalanced. Thus, an additional measurement, Matthews's correlation coefficient (MCC) [47], was employed

to solve the problem; the coefficient can be computed as follows:

$$\begin{aligned} MCC &= \frac{TP \cdot TN - FP \cdot FN}{\sqrt{(TN + FN) \cdot (TN + FP) \cdot (TP + FN) \cdot (TP + FP)}}. \end{aligned} \quad (5)$$

2.4. 10-Fold Cross Validation. Ten-fold cross validation is often used to examine the performance of various classification models [48]. In 10-fold cross validation, the dataset is equally and randomly divided into ten portions. Each portion is used as testing data, and the samples in the remaining nine portions compose the training dataset. Each sample is tested once because each portion is tested once. Compared with the Jackknife test [49, 50], a 10-fold cross-validation test is more efficient and provides similar results for a given dataset. Thus, it was adopted herein to examine the classification model.

2.5. Feature Selection. As described in Section 2.2, each gene is represented by $12,877 + 239 = 13,116$ enrichment scores. To analyze these features and extract key features that contribute the most to the positive and negative gene classification, certain feature-selection methods were employed. This procedure included two stages: (1) using Cramer's coefficient [51, 52] to exclude nonsignificant features and (2) using the minimum redundancy maximum relevance (mRMR) method as well as incremental feature selection (IFS) [53] for additional selection.

Cramer's coefficient [51, 52] is a statistical measure of two variables that was derived from the Pearson Chi-square test [54]; it ranges from 0 to 1. A high Cramer's coefficient for two variables indicates a strong association. Here, for each feature and samples' class labels, Cramer's coefficient was calculated, and features with a Cramer's coefficient lower than 0.1 were excluded.

The remaining features were further refined using the minimum redundancy maximum relevance (mRMR) method and incremental feature selection (IFS), which are feature selection methods that have been widely used in recent years [34, 55–58]. By evaluating a classification model, key features can be extracted from a complicated biological system. The mRMR method has two criteria: max-relevance and min-redundancy. Accordingly, two feature lists can be generated using this method: (1) the MaxRel feature list and (2) the mRMR feature list. Specifically, the former list sorts features according to their contributions to the classification (i.e., only considering the criterion of max-relevance), while the latter list sorts features by considering both the max-relevance and min-redundancy criteria. The MaxRel and mRMR features lists were formulated as follows:

$$\begin{aligned} \text{MaxRel features list : } F_M &= [f_1^M, f_2^M, \dots, f_N^M], \\ \text{mRMR features list : } F_m &= [f_1^m, f_2^m, \dots, f_N^m], \end{aligned} \quad (6)$$

TABLE 1: The number of remaining features for each dataset after the first stage of feature selection.

Dataset	Number of remaining features
D_1	4,288
D_2	3,919
D_3	4,549
D_4	4,663
D_5	4,371
D_6	5,012
D_7	4,877
D_8	3,787
D_9	4,701
D_{10}	4,473

where N denotes the total number of features. A detailed description of the mRMR method can be found in Peng et al.'s paper [53].

Only the mRMR features list was used to extract key features. The extraction procedure is described as follows.

- (1) For the mRMR features list F_m , construct N feature set, say $F_m^1, F_m^2, \dots, F_m^N$, such that $F_m^i = [f_1^i, f_2^i, \dots, f_i^i] (1 \leq i \leq N)$ (i.e., F_m^i contained the first i features in F_m).
- (2) The classifier SMO was evaluated through 10-fold cross validation using features in F_m^i . As described in Section 2.3, ACC, SP, SN and MCC can be obtained.
- (3) The feature set with the maximum MCC is deemed the optimal feature set. For ease in observation, an IFS-curve can be plotted with MCC values as the y -axis and the superscript i of F_m^i as the x -axis.

3. Results and Discussion

3.1. Results of the First Stage of Feature Selection. For each of the 10 datasets $D_1, D_2, \dots, D_{10}$, Cramer's coefficients of the features and samples' class labels were calculated. Accordingly, features with Cramer's coefficients less than 0.1 were excluded, while the remaining features were processed further. The number of remaining features in each dataset is listed in Table 1.

3.2. Results of the Second Stage of Feature Selection. For each dataset D_i , the mRMR, IFS, and SMO methods were used to process the remaining features. The mRMR program was retrieved from <http://research.janelia.org/peng/proj/mRMR/> and was executed with its default parameters. As a result, we generated two feature lists: the MaxRel and mRMR features lists. To reduce the computation time, only the first 500 features in each of the two feature lists were obtained, and they are available in Supplementary Material II.

The IFS and SMO methods were used in accordance with the mRMR features list for each dataset D_i evaluated using 10-fold cross validation. The SNs, SPs, ACCs, and MCCs obtained for each dataset D_i are available in Supplementary

TABLE 2: The number of features in the optimal feature set for each dataset and the MCC value obtained using these features.

Dataset	Number of features in the optimal feature set	Maximum MCC value
D_1	344	0.712699
D_2	226	0.723116
D_3	104	0.873086
D_4	57	0.77142
D_5	146	0.744851
D_6	26	0.699118
D_7	136	0.788893
D_8	462	0.789865
D_9	55	0.704687
D_{10}	70	0.806162
Mean		0.76139

Material III. For clarity, we plotted an IFS-curve for each dataset D_i , which is referred to as IFS-curve- D_i . The five IFS-curves for D_1, D_2, D_3, D_4 , and D_5 are shown in Figure 1(a), while the other five IFS-curves for D_6, D_7, D_8, D_9 , and D_{10} are shown in Figure 1(b); the ten IFS-curves that are plotted in separate coordinates are available in Supplementary Material IV. Generating the maximum MCC for each dataset from Supplementary Material III and IV (listed in column 3 of Table 2) was a straightforward process. Clearly, most MCCs are in the range 0.7 to 0.8, and the mean value was 0.76139. As mentioned in Section 2.5, the features used to obtain the maximum MCC compose the optimal feature set. The number of features in the optimal feature set for each dataset is listed in column 2 of Table 2. The results for dataset D_1 are described as follows. The maximum MCC for the dataset D_1 is 0.712699 (listed in row 2 and column 3 of Table 2) using the first 344 (listed in row 2 and column 2 of Table 2) features in the mRMR features list of dataset D_1 (see Supplementary Material II).

3.3. Analysis of the Optimal Feature Set. As mentioned in Section 3.2, we generated an optimal feature set for each dataset, thereby obtaining 10 optimal feature sets. We combined these optimal feature sets to compose the final optimal feature set, which includes 720 GO terms and 11 KEGG pathways that are available in Supplementary Material V. To discern the distribution of these 731 optimal features, we counted the number of optimal feature sets containing each of 731 features. Figure 2 shows the number of features against the number of optimal feature sets, from which we can see that 400 features were exactly contained in one optimal feature set, 131 features were exactly contained in two optimal feature sets, while others were contained in at least three optimal feature sets. Accordingly, 45.28% (331/731) features were contained in at least two optimal feature sets, indicating that different datasets may induce some common features. It also suggested that some important features for distinguishing AMD-related genes were contained in the final optimal feature set. In

FIGURE 1: IFS-curve for each dataset. Specifically, (a) shows the IFS-curves for the datasets D_1 , D_2 , D_3 , D_4 , and D_5 , while (b) shows the IFS-curves for the datasets D_6 , D_7 , D_8 , D_9 , and D_{10} . The y -axis represents Matthews's correlation coefficient (MCC), and the x -axis represents the number of features involved in the classification model.

FIGURE 2: The number of features against the number of optimal feature sets.

the following sections, features in the final optimal feature set were discussed.

3.3.1. GO Number and Percentage. It is known that GO terms can be divided into the following three types: (1) biological process (BP) GO term, (2) cellular component (CC) GO term, and (3) molecular function (MF) GO term. To efficiently discern the biological meanings and characterize the functional essentiality of the GO terms in the final optimal feature set, we considered the children terms of the aforementioned three types. For clarity, let S_o be the 720 GO terms in the final optimal feature set and S be the children terms of any children term of BP GO term, CC GO term, or MF GO term. To display the distribution of the GO terms in S_o , we calculated the frequency and percentage for each children term of BP GO term, CC GO term, or MF GO term which were defined as $|S_o \cap S|$ and $|S_o \cap S|/|S|$, respectively. Figures 3–8 display the frequency and percentage of children terms of BP GO term, CC GO term, or MF GO term in the final optimal feature set.

(1) *BP GO Terms.* In Figure 3, based on the BP term frequencies, the top five biological process terms are (I) GO: 0009987: cellular process (382); (II) GO: 0065007: biological regulation (301); (III) GO: 0050789: regulation of biological

FIGURE 3: Frequency of children terms of biological process GO terms in the final optimal feature set.

FIGURE 4: Percentage of children terms of biological process GO terms in the final optimal feature set.

process (269); (IV) GO: 0008152: metabolic process (247); and (V) GO: 0050896: response to stimulus (152).

The top four BP terms may indicate that these biological processes are necessary to maintain normal cellular functions

FIGURE 5: Frequency of children terms of cellular component GO terms in the final optimal feature set.

FIGURE 6: Percentage of children terms of cellular component GO terms in the final optimal feature set.

and may lead to AMD due to aberrant behavior in relevant cells.

“Response to stimulus” refers to any process that results from a stimulus, which leads to a change in a state or activity, such as movement and secretion.

FIGURE 7: Frequency of children terms of molecular function GO terms in the final optimal feature set.

FIGURE 8: Percentage of children terms of molecular function GO terms in the final optimal feature set.

For the BP term percentages, as shown in Figure 4, the top five biological process terms are (I) GO: 0001906: cell killing (7.25%); (II) GO: 0040011: locomotion (4.00%); (III) GO: 0002376: immune system process (3.99%); (IV) GO: 0022610: biological adhesion (3.88%), and (V) GO: 0048518: positive regulation of a biological process (2.72%).

Biological adhesion between substrate and cells modulates several critical cellular processes, such as cell locomotion and gene expression [59]. Biological adhesion- and locomotion-related gene dysfunction may result in AMD. Previous research has shown that the immune system, particularly the complement system, is relevant to AMD. Genetic studies also indicate that several complement-related genes, including *CFH*, *complement component 2*, *complement component 3*, *CFHR1*, and *CFHR3*, are highly associated with AMD [60]. Further, complement can enhance the generation

of VEGF (vascular endothelial growth factor), which may strongly facilitate AMD development [61]. Histological studies show the presence of macrophages, lymphocytes, mast cells, and fibroblasts in both atrophic lesions and with retinal neovascularization [61].

(2) *CC GO Terms*. In Figure 5, for the cellular component GO term frequency, the top five CC terms are (I) GO: 0005623: cell (80); (II) GO: 0044464: cell part (64); (III) GO: 0032991: macromolecular complex (27); (IV) GO: 0043226: organelle (24); and (V) GO: 0005576: extracellular region (18). Cell, cell part, organelle, and macromolecular complex inclusion may be attributed to large base numbers of these GO terms.

For the percentage of cellular component terms, as shown in Figure 6, the top five CC terms include (I) GO: 0044420: extracellular matrix part (14.29%); (II) GO: 0031012: extracellular matrix (13.13%); (III) GO: 0044421: extracellular region part (6.94%); (IV) GO: 0005576: extracellular region (6.74%); and (V) GO: 0005623: cell (1.96%).

From the distribution of CC terms, except for the cell term (GO: 0005623), the top four CC terms are associated with the extracellular matrix. Moreover, the extracellular region is relevant to cell adhesion and locomotion, which were mentioned in the biological process GO terms.

The results are also consistent with a recent GWAS study, which identified several new loci with enrichment for genes involved in the extracellular matrix and other activities [18]. Structural damage of extracellular matrix in retinal cells may lead to break point of AMD [62]. Matrix metalloproteinases result in extracellular matrix degradation and are highly related to AMD pathogenesis [63]. Therefore, taken together, these facts suggest that the extracellular matrix plays an important role in AMD.

(3) *MF GO Terms*. In Figure 7, based on the frequency of molecular function terms, the top five MF terms are (I) GO: 0003824: catalytic activity (89); (II) GO: 0005488: binding (72); (III) GO: 0000988: protein binding transcription factor activity (34); (IV) GO: 0004872: receptor activity (34); and (V) GO: 0060089: molecular transducer activity (26).

MF terms related to catalytic activity and binding were highlighted partly due to the large base numbers of these terms. However, this finding may suggest that genes assigned to these two terms are essential to maintain normal function. For example, matrix metalloproteinases, which can degrade extracellular matrix proteins, play an important role in AMD [63]. In addition, highlighting receptor activity and molecular transducer activity indicates that abnormal cellular signal pathway behaviors are involved in AMD patients. For example, the Aryl hydrocarbon receptor, which is responsible for clearing cellular debris and for toxin metabolism, is essential to maintaining normal function in RPE cells, and deficiency of this receptor causes AMD in mice [64].

For the percentage of molecular function terms, as shown in Figure 8, the top five MF terms are (I) GO: 0005198: structural molecule activity (11.76%); (II) GO: 0016209: antioxidant activity (11.54%); (III) GO: 0016247: channel regulator activity (8.33%); (IV) GO: 0030545: receptor regulator activity (5.00%); and (V) GO: 0004872: receptor activity (4.72%).

To our surprise, receptor activity was highlighted in both the frequency and percentage of molecular function terms, which is further evidence of the important role that receptor activity plays in AMD. Antioxidant activity is also highlighted, and oxidative stress [6] is a risk factor correlated with AMD. Channel regulator activity and structural molecule activity may also be involved in AMD.

3.3.2. *The KEGG Pathways in the Final Optimal Set*. Based on the final optimal set, we obtained 11 KEGG pathways, which are (I) hsa00290 (valine, leucine, and isoleucine biosynthesis); (II) hsa00450 (selenocompound metabolism); (III) hsa00512 (mucin-type O-glycan biosynthesis); (IV) hsa03013 (RNA transport); (V) hsa04145 (phagosome); (VI) hsa04610 (complement and coagulation cascades); (VII) hsa04962 (vasopressin-regulated water reabsorption); (VIII) hsa05133 (pertussis); (IX) hsa05146 (viral myocarditis); and (X) hsa05150 (*Staphylococcus aureus* infection); and (XI) hsa05416 (viral myocarditis).

Valine, leucine, and isoleucine biosynthesis (hsa00290) and selenocompound metabolism (hsa00450) are related to amino acid metabolism. Mucin-type O-glycan biosynthesis is associated with modifications of serine or threonine residues of certain proteins. RNA transport from nucleus to cytoplasm is also essential for gene expression. These terms may not be the key factors in AMD, but they may give us suggestions about the AMD development. Phagosome (hsa04145) is also associated with AMD. There are various forms of cell death and phagocytosis in the retina [65]. But failure of retinal pigment epithelial cells and macrophages to phagocytize dying retinal pigment epithelial cells may result in drusen formation and development of AMD [66]. The underlying mechanism of AMD is still unclear, but many studies have highlighted the essential role of the immune system in the development and progression of AMD [67]. Previous studies have revealed a strong association between complement pathway and AMD [20]. Several complement genes including complement 2 (C2) and complement 3 (C3) have been strongly associated with AMD [12, 68]. Except vasopressin-regulated water reabsorption, viral myocarditis (hsa05146) and *Staphylococcus aureus* infection (hsa05150) are all correlated with immunity, which further emphasizes the effect of immunity in AMD.

4. Conclusions

In this study, we performed GO and KEGG enrichment analyses of AMD-related genes. The results suggest that 720 GO terms and 11 KEGG pathways are important factors that contribute to identifying AMD-related genes.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This paper was supported by the National Basic Research Program of China (2011CB510101), Doctoral Innovation Fund of Shanghai Jiaotong University School of Medicine (BXJ201337 and BXJ201234), and National Natural Science Foundation of China (81100679, 81273424, 31371335, and 61202021).

References

- [1] D. Pascolini, S. P. Mariotti, G. P. Pokharel et al., "2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies," *Ophthalmic Epidemiology*, vol. 11, no. 2, pp. 67–115, 2004.
- [2] J. Mitchell and C. Bradley, "Quality of life in age-related macular degeneration: a review of the literature," *Health and Quality of Life Outcomes*, vol. 4, article 97, 2006.
- [3] R. Kawasaki, M. Yasuda, S. J. Song et al., "The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis," *Ophthalmology*, vol. 117, no. 5, pp. 921–927, 2010.
- [4] B. Meyer-Ruesenber and G. Richard, "New insights into the underestimated impairment of quality of life in age-related macular degeneration—a review of the literature," *Klinische Monatsblätter für Augenheilkunde*, vol. 227, no. 8, pp. 646–652, 2010.
- [5] J. Thornton, R. Edwards, P. Mitchell, R. A. Harrison, I. Buchan, and S. P. Kelly, "Smoking and age-related macular degeneration: a review of association," *Eye*, vol. 19, no. 9, pp. 935–944, 2005.
- [6] J. G. Hollyfield, V. L. Bonilha, M. E. Rayborn et al., "Oxidative damage-induced inflammation initiates age-related macular degeneration," *Nature Medicine*, vol. 14, no. 2, pp. 194–198, 2008.
- [7] S. Beatty, H. Koh, M. Phil, D. Henson, and M. Boulton, "The role of oxidative stress in the pathogenesis of age-related macular degeneration," *Survey of Ophthalmology*, vol. 45, no. 2, pp. 115–134, 2000.
- [8] J. K. Shen, A. Dong, S. F. Hackett, W. R. Bell, W. R. Green, and P. A. Campochiaro, "Oxidative damage in age-related macular degeneration," *Histology and Histopathology*, vol. 22, no. 12, pp. 1301–1308, 2007.
- [9] U. Chakravarthy, T. Y. Wong, A. Fletcher, E. Pault, and C. Evans, "Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis," *BMC Ophthalmology*, vol. 10, article 31, 2010.
- [10] S. K. Iyengar, D. Song, B. E. K. Klein et al., "Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration," *The American Journal of Human Genetics*, vol. 74, no. 1, pp. 20–39, 2004.
- [11] D. E. Weeks, Y. P. Conley, H. Tsai et al., "Age-related maculopathy: A genomewide scan with continued evidence of susceptibility loci within the 1q31, 10q26, and 17q25 regions," *The American Journal of Human Genetics*, vol. 75, no. 2, pp. 174–189, 2004.
- [12] B. Gold, J. E. Merriam, J. Zernant et al., "Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration," *Nature Genetics*, vol. 38, no. 4, pp. 458–462, 2006.
- [13] A. O. Edwards, R. Ritter III, K. J. Abel, A. Manning, C. Panhuyssen, and L. A. Farrer, "Complement factor H polymorphism and age-related macular degeneration," *Science*, vol. 308, no. 5720, pp. 421–424, 2005.
- [14] J. A. Fagerness, J. B. Maller, B. M. Neale, R. C. Reynolds, M. J. Daly, and J. M. Seddon, "Variation near complement factor I is associated with risk of advanced AMD," *European Journal of Human Genetics*, vol. 17, no. 1, pp. 100–104, 2009.
- [15] B. M. Neale, J. Fagerness, R. Reynolds et al., "Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC)," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 16, pp. 7395–7400, 2010.
- [16] W. Chen, D. Stambolian, A. O. Edwards et al., "Genetic variants near *TIMP3* and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 16, pp. 7401–7406, 2010.
- [17] S. Arakawa, A. Takahashi, K. Ashikawa et al., "Genome-wide association study identifies two susceptibility loci for exudative age-related macular degeneration in the Japanese population," *Nature Genetics*, vol. 43, no. 10, pp. 1001–1004, 2011.
- [18] L. G. Fritsche, W. Chen, M. Schu et al., "Seven new loci associated with age-related macular degeneration," *Nature Genetics*, vol. 45, pp. 433–439, 2013.
- [19] R. J. Klein, C. Zeiss, E. Y. Chew et al., "Complement factor H polymorphism in age-related macular degeneration," *Science*, vol. 308, no. 5720, pp. 385–389, 2005.
- [20] A. Swaroop, E. Y. Chew, C. B. Rickman, and G. R. Abecasis, "Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration," *Annual Review of Genomics and Human Genetics*, vol. 10, pp. 19–43, 2009.
- [21] M. B. Gorin, "Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics," *Molecular Aspects of Medicine*, vol. 33, no. 4, pp. 467–486, 2012.
- [22] R. R. Priya, E. Y. Chew, and A. Swaroop, "Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management," *Ophthalmology*, vol. 119, no. 12, pp. 2526–2536, 2012.
- [23] Consortium GO, "The gene ontology (GO) project in 2006," *Nucleic Acids Research*, vol. 34, pp. D322–D326, 2006.
- [24] M. Kanehisa and S. Goto, "KEGG: kyoto encyclopedia of genes and genomes," *Nucleic Acids Research*, vol. 28, no. 1, pp. 27–30, 2000.
- [25] H. Ogata, S. Goto, K. Sato, W. Fujibuchi, H. Bono, and M. Kanehisa, "KEGG: kyoto encyclopedia of genes and genomes," *Nucleic Acids Research*, vol. 27, no. 1, pp. 29–34, 1999.
- [26] Z. Yang, N. J. Camp, H. Sun et al., "A variant of the *HTRA1* gene increases susceptibility to age-related macular degeneration," *Science*, vol. 314, no. 5801, pp. 992–993, 2006.
- [27] A. DeWan, M. Liu, S. Hartman et al., "*HTRA1* promoter polymorphism in wet age-related macular degeneration," *Science*, vol. 314, no. 5801, pp. 989–992, 2006.
- [28] T. P. Dryja, C. E. Briggs, E. L. Berson, P. J. Rosenfeld, and M. Abitbol, "ABCR gene and age-related macular degeneration," *Science*, vol. 279, article 1107, 1998.
- [29] A. E. Hughes, N. Orr, H. Esfandiary, M. Diaz-Torres, T. Goodship, and U. Chakravarthy, "A common *CFH* haplotype, with deletion of *CFHR1* and *CFHR3*, is associated with lower risk of age-related macular degeneration," *Nature Genetics*, vol. 38, no. 10, pp. 1173–1177, 2006.
- [30] L. G. Fritsche, N. Lauer, A. Hartmann et al., "An imbalance of human complement regulatory proteins CFHR1, CFHR3 and

- factor H influences risk for age-related macular degeneration (AMD)," *Human Molecular Genetics*, vol. 19, no. 23, pp. 4694–4704, 2010.
- [31] Z. He, T. Huang, X. Shi et al., "Computational analysis of protein tyrosine nitration," in *Proceedings of the 4th International Conference on Computational Systems Biology (ISB '10)*, pp. 35–42, 2010.
 - [32] L. Chen, Z. Qian, K. Fen, and Y. Cai, "Prediction of interactive-ness between small molecules and enzymes by combining gene ontology and compound similarity," *Journal of Computational Chemistry*, vol. 31, no. 8, pp. 1766–1776, 2010.
 - [33] P. Carmona-Saez, M. Chagoyen, F. Tirado, J. M. Carazo, and A. Pascual-Montano, "GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists," *Genome Biology*, vol. 8, no. 1, article R3, 2007.
 - [34] T. Huang, L. Chen, Y. Cai, and K. Chou, "Classification and analysis of regulatory pathways using graph property, biochemical and physicochemical property, and functional property," *PLoS ONE*, vol. 6, no. 9, Article ID e25297, 2011.
 - [35] T. Huang, J. Zhang, Z. Xu et al., "Deciphering the effects of gene deletion on yeast longevity using network and machine learning approaches," *Biochimie*, vol. 94, no. 4, pp. 1017–1025, 2012.
 - [36] L. Chen, B.-Q. Li, and K.-Y. Feng, "Predicting biological functions of protein complexes using graphic and functional features," *Current Bioinformatics*, vol. 8, pp. 545–551, 2013.
 - [37] I. H. Witten and E. Frank, *Data Mining: Practical Machine Learning Tools and Techniques*, Morgan Kaufmann, 2005.
 - [38] L. Chen, L. Lu, K. Feng et al., "Multiple classifier integration for the prediction of protein structural classes," *Journal of Computational Chemistry*, vol. 30, no. 14, pp. 2248–2254, 2009.
 - [39] B. Li, K. Feng, L. Chen, T. Huang, and Y. Cai, "Prediction of protein-protein interaction sites by random forest algorithm with mRMR and IFS," *PLoS ONE*, vol. 7, no. 8, Article ID e43927, 2012.
 - [40] M. Shugay, I. O. de Mendibil, J. L. Vizmanos, and F. J. Novo, "Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions," *Bioinformatics*, vol. 29, pp. 2539–2546, 2013.
 - [41] A. Holzinger and M. Zupan, "KNODWAT: a scientific framework application for testing knowledge discovery methods for the biomedical domain," *BMC Bioinformatics*, vol. 14, no. 1, article 91, 2013.
 - [42] C. Yan, D. Dobbs, and V. Honavar, "A two-stage classifier for identification of protein-protein interface residues," *Bioinformatics*, vol. 20, no. 1, pp. i371–i378, 2004.
 - [43] J. Platt, Ed., *Fast Training of Support Vector Machines Using Sequential Minimal Optimization*, MIT Press, Cambridge, Mass, USA, 1998.
 - [44] S. S. Keerthi, S. K. Shevade, C. Bhattacharyya, and K. R. K. Murthy, "Improvements to Platt's SMO algorithm for SVM classifier design," *Neural Computation*, vol. 13, no. 3, pp. 637–649, 2001.
 - [45] L. Chen, K. Feng, Y. Cai, K. Chou, and H. Li, "Predicting the network of substrate-enzyme-product triads by combining compound similarity and functional domain composition," *BMC Bioinformatics*, vol. 11, article 293, 2010.
 - [46] . Baldi P, S. Brunak, Y. Chauvin, C. Andersen, and H. Nielsen, "Assessing the accuracy of prediction algorithms for classification: an overview," *Bioinformatics*, vol. 16, pp. 412–424, 2000.
 - [47] B. W. Matthews, "Comparison of the predicted and observed secondary structure of T4 phage lysozyme," *Biochimica et Biophysica Acta (BBA)-Protein Structure*, vol. 405, no. 2, pp. 442–451, 1975.
 - [48] R. Kohavi, "A study of cross-validation and bootstrap for accuracy estimation and model selection," in *Proceedings of the 14th international joint conference on Artificial intelligence (IJCAI '95)*, pp. 1137–1143, San Mateo, Calif, USA.
 - [49] L. Chen, W. Zeng, Y. Cai, K. Feng, and K. Chou, "Predicting anatomical therapeutic chemical (ATC) classification of drugs by integrating chemical-chemical interactions and similarities," *PLoS ONE*, vol. 7, no. 4, Article ID e35254, 2012.
 - [50] L. Chen, J. Lu, N. Zhang, T. Huang, and Y.-D. Cai, "A hybrid method for prediction and repositioning of drug Anatomical Therapeutic Chemical classes," *Molecular BioSystems*, vol. 10, pp. 868–877, 2014.
 - [51] H. Cramér, *Mathematical Methods of Statistics*, Princeton University Press, 1946.
 - [52] M. G. Kendall and A. Stuart, *The Advanced Theory of Statistics*, vol. 2 of *Inference and Relationship*, Macmillan, New York, NY, USA, 1973.
 - [53] H. Peng, F. Long, and C. Ding, "Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundanc," *IEEE Transactions on Pattern Analysis and Machine Intelligence*, vol. 27, no. 8, pp. 1226–1238, 2005.
 - [54] K. M. Harrison, T. Kajese, H. I. Hall, and R. Song, "Risk factor redistribution of the national HIV/AIDS surveillance data: an alternative approach," *Public Health Reports*, vol. 123, no. 5, pp. 618–627, 2008.
 - [55] L. Chen, W. Zeng, Y. Cai, and T. Huang, "Prediction of metabolic pathway using graph property, chemical functional group and chemical structural set," *Current Bioinformatics*, vol. 8, no. 2, pp. 200–207, 2013.
 - [56] Y. Zhang, C. Ding, and T. Li, "Gene selection algorithm by combining reliefF and mRMR," *BMC Genomics*, vol. 9, no. 2, article S27, 2008.
 - [57] X. Zhou, Z. Dai, and X. Zou, "Classification of G-protein coupled receptors based on support vector machine with maximum relevance minimum redundancy and genetic algorithm," *BMC Bioinformatics*, vol. 11, article 325, 2010.
 - [58] L. Lu, X. Shi, S. Li et al., "Protein sumoylation sites prediction based on two-stage feature selection," *Molecular Diversity*, vol. 14, no. 1, pp. 81–86, 2010.
 - [59] R. L. Juliano and S. Haskill, "Signal transduction from the extracellular matrix," *Journal of Cell Biology*, vol. 120, no. 3, pp. 577–585, 1993.
 - [60] D. H. Anderson, M. J. Radeke, N. B. Gallo et al., "The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited," *Progress in Retinal and Eye Research*, vol. 29, no. 2, pp. 95–112, 2010.
 - [61] S. M. Whitcup, A. Sodhi, J. P. Atkinson et al., "The role of the immune response in age-related macular degeneration," *International Journal of Inflammation*, vol. 2013, Article ID 348092, 10 pages, 2013.
 - [62] M. R. Al-Ubaidi, M. I. Naash, and S. M. Conley, "A perspective on the role of the extracellular matrix in progressive retinal degenerative disorders," *Investigative Ophthalmology & Visual Science*, vol. 54, pp. 8119–8124, 2013.
 - [63] R. Liutkeviciene, V. Lesauskaite, G. Sinkunaite-Marsalkiene et al., "The role of matrix metalloproteinases polymorphisms in age-related macular degeneration," *Ophthalmic Genetics*, 2013.

- [64] P. Hu, R. Herrmann, A. Bednar, P. Saloupis, and M. A. Dwyer, "Aryl hydrocarbon receptor deficiency causes dysregulated cellular matrix metabolism and age-related macular degeneration-like pathology," *Proceedings of the National Academy of Sciences*, vol. 110, pp. E4069–E4078, 2013.
- [65] W. R. Green and C. Enger, "Age-related macular degeneration histopathologic studies: the 1992 Lorenz E. Zimmerman Lecture. 1992," *Retina (Philadelphia, Pa.)*, vol. 25, no. 5, pp. 1519–1535, 2005.
- [66] J. V. Forrester, "Macrophages eyed in macular degeneration," *Nature Medicine*, vol. 9, no. 11, pp. 1350–1351, 2003.
- [67] J. Ambati, J. P. Atkinson, and B. D. Gelfand, "Immunology of age-related macular degeneration," *Nature Reviews Immunology*, vol. 13, no. 6, pp. 438–451, 2013.
- [68] J. R. W. Yates, T. Sepp, B. K. Matharu et al., "Complement C3 variant and the risk of age-related macular degeneration," *The New England Journal of Medicine*, vol. 357, no. 6, pp. 553–561, 2007.